Westborough Firm Gains FDA Approval For Wound Closer
A needleless wound closure system developed by Wadsworth Medical Technologies of Westborough has been approved by the U.S. Food and Drug Administration.
The system is called DermaLOC and has been classified as a Class I device that presents minimal risk to users. The classification allows Wadsworth to market DermaLOC for human use.
The approval follows a $400,000 accelerator loan Wadsworth received from the Massachusetts Life Sciences Center in April. Wadsworth was one of seven early-stage companies to share $3.4 million in accelerator loans made by the center, which is charged with administering the state's 10-year, $1 billion Life Sciences Initiative.
DermaLOC is an adhesive engineered by Wadsworth to be rapidly placed on wounds. It applies tension to the wound to close it without anesthesia or sutures.
WBJ Web Partners
Most Recent
Most Recent
0 Comments